Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 5/2013

01-10-2013 | Research Article

Evaluating stem and cancerous biomarkers in CD15+CD44+ KYSE30 cells

Authors: Fatemeh B. Rassouli, Maryam M. Matin, Ahamd Reza Bahrami, Kamran Ghaffarzadegan, Hamid Cheshomi, Sara Lari, Bahram Memar, Mun Seng Kan

Published in: Tumor Biology | Issue 5/2013

Login to get access

Abstract

Digestive system cancers are listed among the ten top causes of cancer-related death worldwide. Cancer stem cells (CSCs) are malignant cells that share some of their characteristics with normal stem cells, including self-renewal and multipotency, and also cancer cells, such as drug resistance and metastasis. Despite many reports on CSCs with digestive system origin, identification and characterization of esophageal CSCs have remained elusive. To examine the validity of routine SC, cancer cell and CSC markers in KYSE30 cells, derived from esophageal carcinoma, cells were first characterized by immunofluorescence and RT-PCR techniques, and then the significance of candidate biomarkers was evaluated in retinoic acid-treated cells by flow cytometry and/or real-time RT-PCR. Meanwhile, to study CD15 (a newly introduced CSC marker) expression in digestive tract cancers, human normal and tumoral tissues of esophagus, stomach, and colon were analyzed by immunohistochemistry. Using several experimental approaches, we show that CD44, but not CD15, could serve as a reliable marker for undifferentiated malignant squamous cells of esophagus. In conclusion, our study confirms the role of CD44 as a CSC marker in KYSE30 cells, an esophageal squamous cell carcinoma cell line, and for the first time indicates the expression of CD15 in non-neural stem-like cancer cells. Although the importance of CD15 was not indicated in diagnosis of digestive cancers, further studies are needed to better understand the biological identity and function of this molecule in non-neural malignancies.
Literature
1.
Strong K, Mathers C, Epping-Jordan J, Resnikoff S, Ullrich A. Preventing cancer through tobacco and infection control: how many lives can we save in the next 10 years? Eur J Cancer Prev. 2008;17:153–61.CrossRefPubMed
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
3.
Lu SM, Su M, Tian DP, Deng WD, Zheng YL, Huang HH, et al. Characterization of one newly established esophageal cancer cell line CSEC from a high-incidence area in China. Dis Esophagus. 2008;21:309–15.CrossRefPubMed
4.
Pentenero M, Gandolfo S, Carrozzo M. Importance of tumor thickness and depth of invasion in nodal involvement and prognosis of oral squamous cell carcinoma: a review of the literature. Head Neck. 2005;27:1080–91.CrossRefPubMed
5.
Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18:581–92.CrossRefPubMed
6.
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24:2137–50.CrossRefPubMed
7.
O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res. 2010;12:3113–20.CrossRef
8.
9.
10.
Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Ann Rev Pathol. 2011;6:345–64.CrossRef
11.
Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;1:29(9):e45.
12.
Fabian A, Barok M, Vereb G, Szöllosi J. Die hard: are cancer stem cells the Bruce Willises of tumor biology? Cytometry. 2009;75:67–74.CrossRefPubMed
13.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45.CrossRefPubMed
14.
Naor D, Wallach-Dayan SB, Zahalka MA, Sionov RV. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Sem Cancer Biol. 2008;18:260–7.CrossRef
15.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983–8.PubMedCentralCrossRefPubMed
16.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005;65:10946–51.CrossRefPubMed
17.
Li C, Heidt DG, Dalerba P, Burant CF, Zhang L, Adsay V, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67:1030–7.CrossRefPubMed
18.
Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res. 2008;68:4311–20.PubMedCentralCrossRefPubMed
19.
Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Grazia Prisco M, et al. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res. 2009;15:4299–311.CrossRefPubMed
20.
21.
Du L, Wang H, He L, Zhang J, Ni B, Wang X, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res. 2008;14:6751–60.CrossRefPubMed
22.
Takaishi S, Okumura T, Tu S, Wang SS, Shibata W, Vigneshwaran R, et al. Identification of gastric cancer stem cells using the cell surface marker CD44. Stem Cells. 2009;27:1006–20.PubMedCentralCrossRefPubMed
23.
Zhang C, Li C, He F, Cai Y, Yang H. Identification of CD44+CD24+ gastric cancer stem cells. J Cancer Res Clin Oncol. 2011;37:1679–86.CrossRef
24.
Zhao JS, Li WJ, Ge D, Zhang PJ, Li JJ, Lu CL, et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One. 2011;6:e21419.PubMedCentralCrossRefPubMed
25.
Chen T, Yang K, Yu J, Meng W, Yuan D, Bi F, et al. Identification and expansion of cancer stem cells in tumor tissues and peripheral blood derived from gastric adenocarcinoma patients. Cell Res. 2012;22:248–58.PubMedCentralCrossRefPubMed
26.
Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, et al. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci U S A. 2000;97:14720–5.PubMedCentralCrossRefPubMed
27.
Trubiani O, Zalzal SF, Paganelli R, Marchisio M, Giancola R, Pizzicannella J, et al. Expression profile of the embryonic markers NANOG, OCT-4, SSEA-1, SSEA-4, and frizzled-9 receptor in human periodontal ligament mesenchymal stem cells. J Cell Physiol. 2010;225:123–31.CrossRefPubMed
28.
Strakova Z, Livak M, Krezalek M, Ihnatovych I. Multipotent properties of myofibroblast cells derived from human placenta. Cell Tissue Res. 2008;332:479–88.PubMedCentralCrossRefPubMed
29.
Pruszak J, Sonntag KC, Aung MH, Sanchez-Pernaute R, Isacson O. Markers and methods for cell sorting of human embryonic stem cellderived neural cell populations. Stem Cells. 2007;25:2257–68.PubMedCentralCrossRefPubMed
30.
Pruszak J, Ludwig W, Blak A, Alavian K, Isacson O. CD15, CD24 and CD29 define a surface biomarker code for neural lineage differentiation of stem cells. Stem Cells. 2009;27:2928–40.PubMedCentralPubMed
31.
Ward RJ, Lee L, Graham K, Satkunendran T, Yoshikawa K, Ling E, et al. Multipotent CD15+ cancer stem cells in patched-1-deficient mouse medulloblastoma. Cancer Res. 2009;69:4682–90.CrossRefPubMed
32.
Read TA, Fogarty MP, Markant SL, McLendon RE, Wei Z, Ellison DW, et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell. 2009;15:135–47.PubMedCentralCrossRefPubMed
33.
Wakimoto H, Kesari S, Farrell CJ, Curry Jr WT, Zaupa C, Aghi M, et al. Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors. Cancer Res. 2009;69:3472–81.PubMedCentralCrossRefPubMed
34.
Mao XG, Zhang X, Xue X, Guo G, Wang P, Zhang W, et al. Brain tumor stem-like cells identified by neural stem cell marker CD15. Transl Oncol. 2009;2:247–57.PubMedCentralCrossRefPubMed
35.
Son MJ, Woolard K. NamDH, Lee J, Fine HA. SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma. Cell Stem Cell. 2009;4:440–52.CrossRefPubMed
36.
37.
Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, et al. Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathol. 2005;46:649–58.CrossRef
38.
Sanada Y, Yoshida K, Ohara M, Oeda M, Konishi K, Tsutani Y. Histopathologic evaluation of stepwise progression of pancreatic carcinoma with immunohistochemical analysis of gastric epithelial transcription factor SOX2: comparison of expression patterns between invasive components and cancerous or nonneoplastic intraductal components. Pancreas. 2006;32:164–70.CrossRefPubMed
39.
Matsuoka J, Yashiro M, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Role of the stemness factors Sox2, Oct3/4, and nanog in gastric carcinoma. J Surg Res. 2010;174:130–5.CrossRefPubMed
40.
Wang Q, He W, Lu C, Wang Z, Wang J, Giercksky KE, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29:1233–41.PubMed
41.
Huang D, Gao Q, Guo L, Zhang C, Jiang W, Li H, et al. Isolation and identification of cancer stem-likecells in esophagealcarcinoma celllines. Stem Cells Dev. 2009;18:465–73.CrossRefPubMed
42.
Wang Q, Chen ZG, Du CZ, Wang HW, Yan L, Gu J. Cancer stem cell marker CD133+ tumour cells and clinical outcome in rectal cancer. Histopathol. 2009;55:284–93.CrossRef
43.
Long KB, Hornick JL. SOX2 is highly expressed in squamous cell carcinomas of the gastrointestinal tract. Human Pathol. 2009;40:1768–73.CrossRef
44.
Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238–42.PubMedCentralCrossRefPubMed
45.
Saiki Y, Ishimaru S, Mimori K, Takatsuno Y, Nagahara M, Ishii H, et al. Comprehensive analysis of the clinical significance of inducing pluripotent stemness-related gene expression in colorectal cancer cells. Ann Surg Oncol. 2009;16:2638–44.CrossRefPubMed
46.
Saigusa S, Tanaka K, Toiyama Y, Yokoe T, Okugawa Y, Ioue Y, et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol. 2009;16:3488–98.CrossRefPubMed
47.
Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008;2:333–44.PubMedCentralCrossRefPubMed
48.
Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007;131:861–72.CrossRefPubMed
49.
Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008;26:101–6.CrossRefPubMed
50.
Candi E, Dinsdale D, Rufini A, Salomoni P, Knight RA, Mueller M, et al. TAp63 and DNp63 in cancer and epidermal development. Cell Cycle. 2007;6:274–85.CrossRefPubMed
51.
Dean M, Fojo T, Bates S.Tumour stem cells and drug resistance.Nat Rev Cancer. 2005;5:275–84.
52.
Cruz FD, Matushansky I. Solid tumor differentiation therapy—is it possible? Oncotarget. 2012;3:559–67.PubMed
53.
Andrews PW. Retinoic acid induces neuronal differentiation of a cloned human embryonal carcinoma cell line in vitro. Dev Biol. 1984;103:285–93.CrossRefPubMed
54.
Baldassarre G, Boccia A, Bruni P, Sandomenico C, Barone MV, Pepe S, et al. Retinoic acid induces neuronal differentiation of embryonal carcinoma cells by reducing proteasome-dependent proteolysis of the cyclin-dependent inhibitor p27. Cell Growth Differ. 2000;11:517–26.PubMed
55.
Stevanovic M. Modulation of SOX2 and SOX3 gene expression during differentiation of human neuronal precursor cell line NTERA2. Mol Biol Rep. 2003;30:127–32.CrossRefPubMed
56.
Andrews PW, Nudelman E, Hakomori S-I, Fenderson BA. Different patterns of glycolipid antigens are expressed following differentiation of TERA-2 human embryonal carcinoma cells induced by retinoic acid, hexamethylene bisacetamide (HMBA) or bromodeoxyuridine (BUdR). Differentiation. 1990;43:131–8.
57.
Torma H. Regulation of keratin expression by retinoids. Dermato-Endocrinol. 2011;3:136–40.CrossRef
58.
Virtanen M, Torma H, Vahlquist A. Keratin 4 upregulation by retinoic acid in vivo: a sensitive marker for retinoid bioactivity in human epidermis. J Invest Dermatol. 2000;114:487–93.CrossRefPubMed
59.
Pavez Loriè E, Gånemo A, Borgers M, Wouters L, Blockhuys S, van de Plassche L, et al. Expression of retinoid-regulated genes in lamellar ichthyosis vs. healthy control epidermis: changes after oral treatment with liarozole. Acta Derm Venereol. 2009;89:12–20.CrossRefPubMed
60.
Pavez Loriè E, Cools M, Borgers M, Wouters L, Shroot B, Hagforsen E, et al. Topical treatment with CYP26 inhibitor talarozole (R115866) dose dependently alters the expression of retinoid-regulated genes in normal human epidermis. Br J Dermatol. 2009;160:26–36.CrossRefPubMed
61.
Wanner R, Panteleyev A, Henz BM, Rosenbach T. Retinoic acid affects the expression rate of the differentiation-related genes aryl hydrocarbon receptor, ARNT and keratin 4 in proliferative keratinocytes only. Biochim Biophys Acta. 1996;1317:105–11.CrossRefPubMed
62.
Boisvieux-Ulrich E, Le Pechon-Vallée C, Million K, Baeza-Squiban A, Houcine O, Guennou C, et al. Differential effects of several retinoid receptor-selective ligands on squamous differentiation and apoptosis in airway epithelial cells. Cell Tissue Res. 2000;300:67–81.CrossRefPubMed
63.
Hatakeyama S, Hayashi S, Yoshida Y, Otsubo A, Yoshimoto K, Oikawa Y, et al. Retinoic acid disintegrated desmosomes and hemidesmosomes in stratified oral keratinocytes. J Oral Pathol Med. 2004;33:622–8.CrossRefPubMed
64.
Virtanen M, Sirsjo A, Vahlquist A, Torma H. Keratins 2 and 4/13 in reconstituted human skin are reciprocally regulated by retinoids binding to nuclear receptor RARalpha. Exp Dermatol. 2010;19:674–81.CrossRefPubMed
Metadata
Title
Evaluating stem and cancerous biomarkers in CD15+CD44+ KYSE30 cells
Authors
Fatemeh B. Rassouli
Maryam M. Matin
Ahamd Reza Bahrami
Kamran Ghaffarzadegan
Hamid Cheshomi
Sara Lari
Bahram Memar
Mun Seng Kan
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2013
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-013-0853-5

Other articles of this Issue 5/2013

Tumor Biology 5/2013 Go to the issue

Research Article

PAK5-Egr1-MMP2 signaling controls the migration and invasion in breast cancer cell

Research Article

The potential effect of gender in CYP1A1 and GSTM1 genotype-specific associations with pediatric brain tumor

Research Article

C282Y polymorphism in the HFE gene is associated with risk of breast cancer

Research Article

XRCC1 codon 280 polymorphism and susceptibility to lung cancer: a meta-analysis of the literatures

Review

Prognostic significance of cyclooxygenase-2 in osteosarcoma: a meta-analysis

Research Article

Significant association between Nijmegen breakage syndrome 1 657del5 polymorphism and breast cancer risk
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits